IP Library › Granted Patent US 12,351,832
Granted Patent B2
US 12,351,832 · App. 17/526,467 · Granted Jul 8, 2025

Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography

Inventor: Nicole Brument (Nantes, FR)
Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); UNIVERSITE DE NANTES; CHU NANTES; ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES
C12N7/02B01D15/363B01D69/02C12N7/00C12N15/86A61K48/00B01D2257/91B01D2325/34C12N2750/14121C12N2750/14143C12N2750/14151
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,351,832
App. No.
17/526,467
Granted
Jul 8, 2025
Kind
B2
Abstract

A method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV) is provided. The method includes steps of: a) performing a depth filtration of a cell lysate or a culture supernatant obtained from cells producing rAAV particles, whereby a rAAV-containing clarified composition is provided; b) submitting the rAAV-containing clarified composition to a first step of anion-exchange chromatography on a chromatographic support wherein the rAAV-containing fraction is collected, whereby a first rAAV enriched composition is provided; c) submitting the first rAAV enriched composition at least once to a second step of anion-exchange chromatography on a chromatographic support wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; d) submitting the second rAAV enriched composition to a step of tangential flow filtration to provide purified recombinant Adeno-Associated Virus particles (rAAV).

Claims (14)

1. A method for obtaining purified recombinant Adeno-Associated Virus (rAAV) particles, comprising the steps of:

a) performing a depth filtration of a starting material previously obtained from cells producing rAAV particles, the said starting material being a cell lysate or a culture supernatant, whereby a rAAV-containing clarified composition is provided;

b) submitting the rAAV-containing clarified composition to a first step of anion-exchange chromatography on a chromatographic support, wherein elution is performed by using a linear salt gradient and wherein the rAAV-containing fraction is collected, whereby a first rAAV enriched composition is provided;

c) submitting the first rAAV enriched composition at least once to a second step of anion-exchange chromatography on a chromatographic support wherein elution is performed by using a linear salt gradient and wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided;

d) submitting the second rAAV enriched composition to a step of tangential flow filtration, whereby purified recombinant Adeno-Associated Virus particles (rAAV) are provided;

wherein said rAAV particles belong to an AAV5 capsid serotype and

wherein the purified rAAV particles have an amount of residual host cell DNA equal or inferior to 50 ng per dose of 10 12 vector genomes (vg) of the rAAV particles that belong to the AAV5 capsid serotype.

2. The method according to claim 1 , wherein at the end of step a), the pH of the rAAV-containing clarified composition is adjusted at a basic pH so as to ensure optimal retention of the rAAV particles on the chromatographic support used at step b).

3. The method according to claim 1 , wherein the chromatographic support at step b) or step c) is a monolithic chromatographic support.

4. The method according to claim 1 , wherein step d) is performed by using a filter membrane having a molecular weight cut-off value ranging from 50 kDa to 150 kDa.

5. The method according to claim 1 , wherein the rAAV particle contains DNA comprising an expression cassette encoding human phosphodiesterase 6B-beta.

6. The method according to claim 1 , wherein the purified rAAV particles have a purity of at least 90%.

7. The method according to claim 1 , wherein the final yield of purified rAAV particles is equal or superior to 10%.

8. The method according to claim 5 , wherein the final yield of purified rAAV particles is equal or superior to 15%.

Assignments (2)
CHANGE OF NAME Recorded Apr 20, 2022
From: UNIVERSITÉ DE NANTES
To: NANTES UNIVERSITÉ
Reel/Frame 059646/0865 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2021
From: BRUMENT, NICOLE
To: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); UNIVERSITE DE NANTES; CHU NANTES; ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES
Reel/Frame 058114/0105 →
Priority Claims (1)
EP 15305187 · Feb 9, 2015 · regional
Continuity (3)
Continuation 15549279
Related Publication 20220098618A1 · Mar 31, 2022
Related Publication 20240060054A9 · Feb 22, 2024
References Cited (60)
US 5139941A · Muzyczka et al. · 1992 [cited by applicant]
US 5173414A · Lebkowski et al. · 1992 [cited by applicant]
US 6376237B1 · Colosi · 2002 [cited by applicant]
US 7419817B2 · Chiorini et al. · 2008 [cited by applicant]
US 7625570B1 · Schaffer et al. · 2009 [cited by applicant]
US 20010043916A1 · McNeilly et al. · 2001 [cited by applicant]
US 20040106184A1 · Senesac · 2004 [cited by examiner]
WO 1992001070A1 · 1992 [cited by applicant]
WO 1993003769A1 · 1993 [cited by applicant]
WO 2002012455A1 · 2002 [cited by applicant]
WO 2003097797A2 · 2003 [cited by applicant]
WO 2004020971 · 2004 [cited by applicant]
WO 2004113494A2 · 2004 [cited by applicant]
WO 2007059473 · 2007 [cited by applicant]
WO 2007134325 · 2007 [cited by applicant]
WO 2010130753A1 · 2010 [cited by applicant]
WO 2010148143A1 · 2010 [cited by applicant]
WO 2011066454A1 · 2011 [cited by applicant]
WO 2011094198 · 2011 [cited by applicant]
WO 2012010280A1 · 2012 [cited by applicant]
Allocca et al. “AAV-mediated gene replacement, either alone or in combination with physical and pharmacological agents, results in partial and transient protection from photoreceptor degeneration associated with BPDE de… [cited by examiner]
Qu, Weihong, et al. “Scalable downstream strategies for purification of recombinant adeno-associated virus vectors in light of the properties.” Current pharmaceutical biotechnology 16.8 (2015): 684-695. (Year: 2015). [cited by examiner]
Allocca et al. “AAV-mediated gene replacement, either alone or in combination with physical and pharmacological agents, results in partial and transient protection from photoreceptor degeneration associated with βPDE de… [cited by examiner]
Oksanen, Hanna M., Ausra Domanska, and Dennis H. Bamford. “Monolithic ion exchange chromatographic methods for virus purification.” Virology 434.2 (2012): 271-277. (Year: 2012). [cited by examiner]
Le Meur, G., Stieger, K., Smith, A. et al. Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Ther 14, 292-303 (2007). (Y… [cited by examiner]
Gao et al. “Empty virions in AAV8 vector preparations reduce transduction efficiency and may cause total viral particle dose-limiting side effects.” Molecular Therapy—Methods & Clinical development, 2014, 1(9):20139. [cited by applicant]
Uchida et al. “Early Life Stress Enhances Behavioral Vulnerability to Stress through the Activation of REST4-Mediated Gene Transcription in the Medial Prefrontal Cortex of Rodents.” The Journal of Neuroscience, Nov. 10,… [cited by applicant]
Allay et al. “Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial.” Human gene therapy (2011) vol. 22,5: 595-604. [cited by applicant]
Allocca et al., “AAV-mediated gene replacement, either alone or in combination with physical and pharmacological agents, results in partial and transient protection from photoreceptor degeneration associated with betaPD… [cited by applicant]
Ayuso et al., “Manufacturing and characterization of a recombinant adeno-associated virus type 8 reference standard material”. Hum Gene Ther. Nov. 2014;25(11):977-87. [cited by applicant]
Berns & Bohensky, 1987. “Adeno-associated viruses: an update”. In Maramorosch, Murphy, & Shatkin (Eds.), Advances in Virus Research (vol. 32, pp. 243-307). New York, NY: Academic Press, Inc. [cited by applicant]
Blouin et al. “Improving rAAV production and purification: towards the definition of a scaleable process.” The journal of gene medicine vol. 6 Suppl 1 (2004): S223-8. [cited by applicant]
Brument et al., “A versatile and scalable two-step ion-exchange chromatography process for the purification of recombinant adeno-associated virus serotypes-2 and -5”. Mol Ther. Nov. 2002;6(5):678-86. [cited by applicant]
Carter, “Adeno-associated virus vectors”. Curr Opin Biotechnol. Oct. 1992;3(5):533-9. [cited by applicant]
Chu et al., “SV40 DNA transfection of cells in suspension: analysis of efficiency of transcription and translation of T-antigen”. Gene. Mar. 1981;13(2):197-202. [cited by applicant]
Heukeshoven & Dernick, “Characterization of a solvent system for separation of water-insoluble poliovirus proteins by reversed-phase high-performance liquid chromatography”. J Chromatogr. Jun. 19, 1985; 326:91-101. [cited by applicant]
Kotin, “Prospects for the use of adeno-associated virus as a vector for human gene therapy”. Hum Gene Ther. Jul. 1994;5(7):793-801. [cited by applicant]
Le Meur et al., “Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium”. Gene Ther. Feb. 2007;14(4):292-303. [cited by applicant]
Lebkowski et al., “Adeno-associated virus: a vector system for efficient introduction and integration of DNA into a variety of mammalian cell types”. Mol Cell Biol. Oct. 1988;8(10):3988-96. [cited by applicant]
McCarty et al., “Sequences required for coordinate induction of adeno-associated virus p19 and p40 promoters by Rep protein”. J Virol. Jun. 1991;65(6):2936-45. [cited by applicant]
Muzyczka, “Use of adeno-associated virus as a general transduction vector for mammalian cells”. Curr Top Microbiol Immunol. 1992; 158:97-129. [cited by applicant]
Oksanen et al., “Monolithic ion exchange chromatographic methods for virus purification”. Virology. Dec. 20, 2012;434(2):271-7. [cited by applicant]
Petit et al., “Restoration of vision in the pde6β-deficient dog, a large animal model of rod-cone dystrophy”. Mol Ther. Nov. 2012;20(11):2019-30. [cited by applicant]
Qu et al. “Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography.” Journal of virological methods (2007) vol. 140,1-2: 183-92. [cited by applicant]
Salvetti et al., “Factors influencing recombinant adeno-associated virus production”. Hum Gene Ther. Mar. 20, 1998;9(5):695-706. [cited by applicant]
Samulski et al., “Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression”. J Virol. Sep. 1989;63(9):3822-8. [cited by applicant]
Toublanc et al. “Identification of a replication-defective herpes simplex virus for recombinant adeno-associated virus type 2 (rAAV2) particle assembly using stable producer cell lines.” The journal of gene medicine vol… [cited by applicant]
Urabe et al. “Removal of empty capsids from type 1 adeno-associated virus vector stocks by anion-exchange chromatography potentiates transgene expression.” Molecular therapy: the journal of the American Society of Gene … [cited by applicant]
Wang et al. “Production and purification of recombinant adeno-associated vectors.” Methods in molecular biology (Clifton, N.J.) vol. 807 (2011): 361-404. [cited by applicant]
Zhou et al. “PEG-modulated column chromatography for purification of recombinant adeno-associated virus serotype 9.” Journal of virological methods, Apr. 2011, vol. 173,1: 99-107. [cited by applicant]
Burova, E. & Ioffe, E., “Chromatographic purification of recombinant adenoviral and adeno-associated viral vectors: methods and implications”, Gene Therapy 12, 2005. [cited by applicant]
Merck Millipore, “Data Sheet: Polysep II Filters”. [cited by applicant]
Potter, M. et al., “A simplified purification protocol for recombinant adeno-associated virus vectors”, Molecular Therapy—Methods & Clinical Development 1, 2014. [cited by applicant]
Clément, N, & Grieger, J., “Manufacturing of recombinant adeno-associated viral vectors for clinical trials”, Molecular Therapy—Methods & Clinical Development 3, 2016. [cited by applicant]
Qu, G. et al., “Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography”, Journal of Virological Methods 140, 2007. [cited by applicant]
GE Healthcare, “Ion Exchange Chromatography & Chromatofocusing Principles and Methods”, 2010. [cited by applicant]
Nestola, P. et al., “Improved Virus Purification Processes for Vaccines and Gene Therapy”, Biotechnology and Bioengineering 112:5, 2015. [cited by applicant]
Pall Corporation, “Profile UP Filters”, Filtration. Separation. Solution., 2011. [cited by applicant]
Lajmi, A. et al., “A Membrane Chromatography Application: A Rapid, High Capacity Gene Therapy Vector Purification Tool”, Taylor & Francis Group, 2007. [cited by applicant]
Li, X. et al., “Gene Therapy Rescues Cone Structure and Function in the 3-Month-Old rd12 Mouse: A Model for Midcourse RPE65 Leber Congenital Amaurosis”, Investigative Ophthalmology & Visual Science, Jan. 2011, vol. 52, … [cited by applicant]